Chatterjee Sayan, Nalla Lakshmi Vineela, Sharma Monika, Sharma Nishant, Singh Aditya A, Malim Fehmina Mushtaque, Ghatage Manasi, Mukarram Mohd, Pawar Abhijeet, Parihar Nidhi, Arya Neha, Khairnar Amit
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat 382355, India.
Department of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Andhra Pradesh 522302, India.
ACS Pharmacol Transl Sci. 2023 Feb 27;6(3):334-354. doi: 10.1021/acsptsci.2c00181. eCollection 2023 Mar 10.
Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) which was identified in Wuhan, China in December 2019 and jeopardized human lives. It spreads at an unprecedented rate worldwide, with serious and still-unfolding health conditions and economic ramifications. Based on the clinical investigations, the severity of COVID-19 appears to be highly variable, ranging from mild to severe infections including the death of an infected individual. To add to this, patients with comorbid conditions such as age or concomitant illnesses are significant predictors of the disease's severity and progression. SARS-CoV-2 enters inside the host cells through ACE2 (angiotensin converting enzyme2) receptor expression; therefore, comorbidities associated with higher ACE2 expression may enhance the virus entry and the severity of COVID-19 infection. It has already been recognized that age-related comorbidities such as Parkinson's disease, cancer, diabetes, and cardiovascular diseases may lead to life-threatening illnesses in COVID-19-infected patients. COVID-19 infection results in the excessive release of cytokines, called "cytokine storm", which causes the worsening of comorbid disease conditions. Different mechanisms of COVID-19 infections leading to intensive care unit (ICU) admissions or deaths have been hypothesized. This review provides insights into the relationship between various comorbidities and COVID-19 infection. We further discuss the potential pathophysiological correlation between COVID-19 disease and comorbidities with the medical interventions for comorbid patients. Toward the end, different therapeutic options have been discussed for COVID-19-infected comorbid patients.
冠状病毒病(COVID-19)由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,该病毒于2019年12月在中国武汉被发现,危及人类生命。它在全球以前所未有的速度传播,带来了严重且仍在不断显现的健康问题和经济影响。根据临床调查,COVID-19的严重程度似乎差异很大,从轻度感染到严重感染,包括感染者死亡。此外,患有年龄或合并症等合并疾病的患者是疾病严重程度和进展的重要预测指标。SARS-CoV-2通过血管紧张素转换酶2(ACE2)受体表达进入宿主细胞;因此,与较高ACE2表达相关的合并症可能会增加病毒进入以及COVID-19感染的严重程度。人们已经认识到,帕金森病、癌症、糖尿病和心血管疾病等与年龄相关的合并症可能会导致COVID-19感染患者出现危及生命的疾病。COVID-19感染会导致细胞因子过度释放,即所谓的“细胞因子风暴”,这会使合并疾病状况恶化。人们已经推测了导致COVID-19患者入住重症监护病房(ICU)或死亡的不同感染机制。本综述深入探讨了各种合并症与COVID-19感染之间的关系。我们还将进一步讨论COVID-19疾病与合并症之间潜在的病理生理相关性以及针对合并症患者的医学干预措施。最后,我们讨论了针对COVID-19感染合并症患者的不同治疗选择。